Nemaura Medical Inc.
NMRD · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.46 | -0.07 | -0.68 | 1.47 |
| FCF Yield | -40.38% | -7.30% | -4.01% | -3.00% |
| EV / EBITDA | -4.42 | -14.12 | -36.38 | -25.79 |
| Quality | ||||
| ROIC | -103.87% | -35.66% | -12.60% | 2,513.26% |
| Gross Margin | -1,916.30% | 31.67% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.60 | 0.47 | 0.96 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -20.51% | -9.16% | -86.71% | -0.54% |
| Safety | ||||
| Net Debt / EBITDA | -1.36 | -0.20 | 1.55 | 0.02 |
| Interest Coverage | -1.50 | -1.14 | -2.28 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.89 | 0.23 | 0.12 | 0.00 |
| Cash Conversion Cycle | 2,276.31 | 1,506.09 | 2,221.55 | 0.00 |